Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 229 publications
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026
Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol.
Journal: Clinical and translational radiation oncology
Published: April 14, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 07, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 18, 2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 09, 2025
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 28, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 19, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: May 22, 2025
Last Updated: 09/26/2026